REPORT FROM THE 2009 AAN ANNUAL MEETING – Two studies have investigated the potential benefits of rituximab, a monoclonal antibody that targets CD20 B cells, in primary- and secondary-progressive MS (PPMS, SPMS).
Read More
Neurology
Donepezil slows decline in ADL
July 7, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – A pooled analysis (n=2,177) of six randomized double-blind trials of donepezil in Alzheimers disease has found that treatment is associated with a reduced decline in activities of daily living (ADL) (Gauthier et al. AAN 2009; abstract P06.079).
Read More
Risk of Parkinsons disease with cumulative lead exposure
July 7, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – A new multicentre study has found an increasing risk of Parkinsons disease with cumulative exposure to lead (Weisskopf et al. AAN 2009; abstract S23.001).
Read More
Global survey of migraine prevalence
July 7, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – An internet survey has been used to estimate the global prevalence of chronic migraine, defined as >15 headache days per month and a clinical diagnosis of migraine (Varon et al. AAN 2009; abstract P06.001).
Read More
Cortical thinning in Alzheimers disease
June 22, 2009REPORT FROM THE 2009 AAN ANNUAL MEETING – Several recent studies have indicated that cortical thickness measures may be a useful MRI marker to distinguish mild cognitive impairment (MCI) from normal aging (Wang et al. AJNR Am J Neuroradiol 2009; epublished March 11, 2009), identify patients at risk of developing Alzheimers disease (Bakkour et al. Neurology 2009;72:1048-1055), and to differentiate Alzheimers disease from frontotemporal dementia (Du et al. Brain 2007;130(pt 4):1159-1166; free download at http://brain.oxfordjournals.org/cgi/content/full/130/4/1159).
Read More